Trial Profile
A Phase 1 Dose-Escalation Study of XL765 in Combination With Erlotinib in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2015
Price :
$35
*
At a glance
- Drugs Voxtalisib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 02 Feb 2012 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2011 Trial company Sanofi and lead trial centre added as reported by ClinicalTrials.gov.